Blisstree » EGFR http://www.blisstree.com Family, Health, Home and Lifestyles Thu, 24 Dec 2009 23:47:29 +0000 http://wordpress.org/?v=2.8.4 en hourly 1 Cannabis Compound Significantly Reduced Lung Cancer Tumor http://www.blisstree.com/articles/cannabis-compound-significantly-reduced-lung-cancer-tumor-57/ http://www.blisstree.com/articles/cannabis-compound-significantly-reduced-lung-cancer-tumor-57/#comments Thu, 19 Apr 2007 15:02:31 +0000 Gloria Gamat http://cancercommentary.com/2007/04/19/cannabis-compound-significantly-reduced-lung-cancer-tumor/ Post from: Blisstree

Cannabis Compound Significantly Reduced Lung Cancer Tumor

]]> Delta-tetrahydrocannabinol (THC), the active compound in marijuana has been found to cut tumor growth by half in common lung cancer, aside from significantly reducing the ability of the cancer to spread.

Conducted by researchers at Harvard University, this is the first study to demonstrate that a cannabinoid compound inhibits EGF-induced growth and migration in epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer cell lines.

According to Anju Preet, Ph.D., a researcher in the Division of Experimental Medicine:

“The beauty of this study is that we are showing that a substance of abuse, if used prudently, may offer a new road to therapy against lung cancer.”

The study’s findings suggest that THC or other designer agents that activate cannabinoid receptors CB1 and CB2 might be used in a targeted fashion to treat lung cancer.

Find more details from the full report.

Post from: Blisstree

Cannabis Compound Significantly Reduced Lung Cancer Tumor

]]> http://www.blisstree.com/articles/cannabis-compound-significantly-reduced-lung-cancer-tumor-57/feed/ 0 TYKERB® (lapatinib) in Combination With Xeloda® (capecitabine): USFDA-approved for the Treatment of Advanced or Metastatic Breast Cancer http://www.blisstree.com/articles/tykerb%c2%ae-lapatinib-in-combination-with-xeloda%c2%ae-capecitabine-usfda-approved-for-the-treatment-of-advanced-or-metastatic-breast-cancer-57/ http://www.blisstree.com/articles/tykerb%c2%ae-lapatinib-in-combination-with-xeloda%c2%ae-capecitabine-usfda-approved-for-the-treatment-of-advanced-or-metastatic-breast-cancer-57/#comments Fri, 16 Mar 2007 05:01:44 +0000 Gloria Gamat http://cancercommentary.com/2007/03/16/tykerb%c2%ae-lapatinib-in-combination-with-xeloda%c2%ae-capecitabine-usfda-approved-for-the-treatment-of-advanced-or-metastatic-breast-cancer/ Post from: Blisstree

TYKERB® (lapatinib) in Combination With Xeloda® (capecitabine): USFDA-approved for the Treatment of Advanced or Metastatic Breast Cancer

]]> A product of GlaxoSmithKile Plc – TYKERB® (lapatinib) – has recently been approved by the USFDA, in combination with Xeloda® (capecitabine), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

TYKERB® (a pdf file) – a small molecule that inhibits the tyrosine kinase components of the EGFR (ErbB1) and HER2 (ErbB2) receptors – is the first targeted, once-daily oral treatment option for the abovementioned patient population.

This approval reflects more than 16 years of research, including more than 60 clinical trials and investigator-initiated collaborative research studies. TYKERB® is designed to interfere with discrete cellular processes or disease mechanisms prevalent in cancer.

Within two weeks of the approval, TYKERB® will be available in the United States.

Find more details from the full report.

Post from: Blisstree

TYKERB® (lapatinib) in Combination With Xeloda® (capecitabine): USFDA-approved for the Treatment of Advanced or Metastatic Breast Cancer

]]> http://www.blisstree.com/articles/tykerb%c2%ae-lapatinib-in-combination-with-xeloda%c2%ae-capecitabine-usfda-approved-for-the-treatment-of-advanced-or-metastatic-breast-cancer-57/feed/ 1